MINNEAPOLIS, MN / ACCESSWIRE / March 12, 2020 / Celcuity Inc. (NASDAQ:CELC), a functional cellular analysis company that is developing companion diagnostic tests designed to expand the eligible patient ...
MINNEAPOLIS, MN / ACCESSWIRE / December 11, 2019 / Celcuity Inc. (Nasdaq:CELC), a dynamic cellular analysis company developing diagnostic tests to identify new patient populations for targeted therapies, ...
Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
MINNEAPOLIS, MN / ACCESSWIRE / February 27, 2020 / Celcuity Inc. (CELC), a functional cellular analysis company that is developing companion diagnostic tests designed to expand the eligible patient populations for targeted therapies, announced that it will release its financial results for the fourth quarter and fiscal year 2019 after the stock market close on Thursday, March 12, 2020.
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
MINNEAPOLIS, MN / ACCESSWIRE / April 23, 2020 / Celcuity Inc. (CELC), a functional cellular analysis company that is developing companion diagnostic tests designed to expand the eligible patient populations for targeted therapies, announced that it will release its financial results for the first quarter 2020 after the stock market close on Thursday, May 7, 2020. Our proprietary CELsignia diagnostic platform is currently the only commercially ready technology that we are aware of that uses a patient's living tumor cells to identify the cellular activity that may be driving a patient's cancer.
Every investor in Celcuity Inc. (NASDAQ:CELC) should be aware of the most powerful shareholder groups. Institutions...
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Significant progress made in development of new, highly precise diagnostics using proprietary CELsignia platform Expect to announce new clinical trial collaborations with pharmaceutical companies and trial ...
While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Celcuity, Inc. (NASDAQ:CELC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30 PM Eastern ...
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.